{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:26:24Z","timestamp":1788452784099,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"am","delay-in-days":264,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["AI153400"],"award-info":[{"award-number":["AI153400"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.coviro.2025.101477","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:04:49Z","timestamp":1755824689000},"page":"101477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Status of advanced respiratory syncytial virus antiviral therapeutics 2025"],"prefix":"10.1016","volume":"73","author":[{"given":"Claire E","family":"Ruckel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef D","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-2107","authenticated-orcid":false,"given":"Richard K","family":"Plemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2025.101477_bib1","unstructured":"H.\u00a0Jain, J.W. Schweitzer, N.A. Justice: Respiratory Syncytial Virus Infection in Children. 2023 June 23 2023 03\/13\/2025]; Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459215\/\u3009."},{"key":"10.1016\/j.coviro.2025.101477_bib2","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1007\/s00018-020-03557-0","article-title":"Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics","volume":"77","author":"Efstathiou","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coviro.2025.101477_bib3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3181\/00379727-92-22538","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Blount","year":"1956","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.coviro.2025.101477_sbref3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2025.101477_bib5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jix489","article-title":"Prefusion F, postfusion F, G antibodies, and disease severity in infants and young children with acute respiratory syncytial virus infection","volume":"216","author":"Capella","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2025.101477_bib6","unstructured":"CDC. Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over. 2024; Available from: \u3008https:\/\/www.cdc.gov\/vaccines\/vpd\/rsv\/hcp\/older-adults.html#:\u223c:text=GSK's%20AREXVY%20consists%20of%20a,but%20at%20a%20lower%20dose\u3009."},{"key":"10.1016\/j.coviro.2025.101477_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-01002-y","article-title":"Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization","volume":"9","author":"Hong-Nguyen","year":"2024","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.coviro.2025.101477_bib8","article-title":"Use of the abrysvo vaccine in pregnancy to prevent respiratory syncytial virus in infants: a review","volume":"31","author":"Patel","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.coviro.2025.101477_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.ajt.2023.09.003","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2023","volume":"23","author":"Melgar","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coviro.2025.101477_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2303796","article-title":"Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States","volume":"20","author":"La","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coviro.2025.101477_bib11","first-page":"769","article-title":"Palivizumab for the prevention of respiratory syncytial virus infection","volume":"56","author":"Rogovik","year":"2010","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.coviro.2025.101477_bib12","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2025.101477_bib13","first-page":"372","article-title":"Pediatric antiviral stewardship: defining the potential role of ribavirin in respiratory syncytial virus-associated lower respiratory illness","volume":"23","author":"Hoover","year":"2018","journal-title":"J Pedia Pharm Ther"},{"key":"10.1016\/j.coviro.2025.101477_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/mmi.15133","article-title":"Respiratory syncytial virus entry mechanism in host cells: a general overview","volume":"120","author":"Cadena-Cruz","year":"2023","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.coviro.2025.101477_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105948","article-title":"Direct-acting antivirals for RSV treatment, a review","volume":"229","author":"Bonneux","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2025.101477_bib16","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.7150\/ijbs.64762","article-title":"Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.coviro.2025.101477_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2025.101477_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01884-19","article-title":"A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein","volume":"64","author":"DeVincenzo","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2025.101477_bib19","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jac\/dky415","article-title":"Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans","volume":"74","author":"Patel","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2025.101477_bib20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/infdis\/jiaa716","article-title":"Safety and antiviral effects of nebulized PC786 in a respiratory syncytial virus challenge study","volume":"225","author":"DeVincenzo","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2025.101477_bib21","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40272-024-00625-x","article-title":"CROCuS, a phase ii study evaluating the antiviral activity, clinical outcomes, and safety of rilematovir in children aged >\/= 28 days and <\/= 3 years with acute respiratory tract infection due to respiratory syncytial virus","volume":"26","author":"Ferrero","year":"2024","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.coviro.2025.101477_bib22","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/cid\/ciz1167","volume":"71","author":"Marty","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2025.101477_bib23","unstructured":"Masson, G : 'Ongoing Challenges' Force Pfizer to Scrap Oral RSV med From ReViral Buyout. 2024; Available from: \u3008https:\/\/www.fiercebiotech.com\/biotech\/ongoing-challenges-pfizers-oral-rsv-med-prompt-trial-terminations\u3009."},{"key":"10.1016\/j.coviro.2025.101477_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288271","article-title":"Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results","volume":"18","author":"Oey","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2025.101477_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2014.12.012","article-title":"Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen","volume":"115","author":"Laganas","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2025.101477_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/srep25806","article-title":"Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication","volume":"6","author":"Bailly","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2025.101477_sbref24","doi-asserted-by":"crossref","first-page":"E3441","DOI":"10.1073\/pnas.1405198111","article-title":"Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors","volume":"111","author":"Yan","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coviro.2025.101477_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/irv.12503","article-title":"The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin","volume":"11","author":"Kim","year":"2017","journal-title":"Influenza Other Respir Virus"},{"key":"10.1016\/j.coviro.2025.101477_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00170-x","article-title":"Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor","volume":"8","author":"Roymans","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2025.101477_bib30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume":"58","author":"Mackman","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2025.101477_sbref28","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2025.101477_bib32","unstructured":"Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585. 2017; Available from: \u3008https:\/\/www.globenewswire.com\/news-release\/2017\/02\/01\/913102\/0\/en\/Aviragen-Therapeutics-Announces-Top-Line-Results-from-Phase-2a-RSV-Challenge-Study-of-BTA585.html\u3009."},{"key":"10.1016\/j.coviro.2025.101477_sbref29","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2313551","article-title":"Ziresovir in hospitalized infants with respiratory syncytial virus infection","volume":"391","author":"Zhao","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2025.101477_sbref30","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01205-21","article-title":"Mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in respiratory syncytial virus fusion protein","volume":"95","author":"Tang","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101477_bib35","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/JVI.77.9.5054-5064.2003","article-title":"Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein","volume":"77","author":"Douglas","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101477_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02312-19","article-title":"Assessment of drug resistance during phase 2b clinical trials of presatovir in adults naturally infected with respiratory syncytial virus","volume":"64","author":"Porter","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2025.101477_sbref33","article-title":"Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: a phase 2 proof-of-concept trial","volume":"17","author":"Huang","year":"2023","journal-title":"Influenza Other Respir Virus"},{"key":"10.1016\/j.coviro.2025.101477_bib38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/infdis\/jiaa028","article-title":"Drug resistance assessment following administration of respiratory syncytial virus (RSV) fusion inhibitor presatovir to participants experimentally infected with RSV","volume":"222","author":"Stray","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2025.101477_sbref35","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01385-24","article-title":"A new mechanism of respiratory syncytial virus entry inhibition by small-molecule to overcome K394R-associated resistance","volume":"15","author":"Song","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2025.101477_bib40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/nar\/gkv1286","article-title":"Signature motifs of GDP polyribonucleotidyltransferase, a non-segmented negative strand RNA viral mRNA capping enzyme, domain in the L protein are required for covalent enzyme-pRNA intermediate formation","volume":"44","author":"Neubauer","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coviro.2025.101477_bib41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/molecules21060766","article-title":"Chemical incorporation of chain-terminating nucleoside analogs as 3\u2019-blocking DNA damage and their removal by human ERCC1-XPF endonuclease","volume":"21","author":"Yamamoto","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.coviro.2025.101477_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.abj5508","article-title":"4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication","volume":"375","author":"Sourimant","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.coviro.2025.101477_sbref39","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2025.101477_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-biochem-013118-111843","article-title":"Ribonucleotide reductases: structure, chemistry, and metabolism suggest new therapeutic targets","volume":"89","author":"Greene","year":"2020","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.coviro.2025.101477_bib45","doi-asserted-by":"crossref","first-page":"40847","DOI":"10.1074\/jbc.M106743200","article-title":"Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase","volume":"276","author":"Johnson","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2025.101477_bib46","doi-asserted-by":"crossref","first-page":"9489","DOI":"10.1074\/jbc.M209397200","article-title":"Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2025.101477_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.virusres.2017.01.008","article-title":"Polymerases of paramyxoviruses and pneumoviruses","volume":"234","author":"Fearns","year":"2017","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2025.101477_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3851\/IMP2896","article-title":"The discovery and development of antiretroviral agents","volume":"19","author":"Lange","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2025.101477_bib49","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2025.101477_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004995","article-title":"Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate","volume":"11","author":"Deval","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2025.101477_bib51","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMoa1413275","article-title":"Activity of oral ALS-008176 in a respiratory syncytial virus challenge study","volume":"373","author":"DeVincenzo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2025.101477_bib52","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","article-title":"Discovery of GS-5245 (Obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys","volume":"66","author":"Mackman","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2025.101477_bib53","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2025.101477_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2025.101477_bib55","series-title":"Receives U.S. FDA Fast Track Designation for the Novel Anti-Respiratory Syncytial Virus Drug Candidate S-337395","author":"Shionogi & Co., L.a.U.C","year":"2024"},{"key":"10.1016\/j.coviro.2025.101477_bib56","series-title":"Enanta Pharmaceuticals announces positive data from a phase 1 clinical study of EDP-323, an oral, L-protein inhibitor in development for the treatment of respiratory syncytial virus","author":"Entanta","year":"2023"},{"key":"10.1016\/j.coviro.2025.101477_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00737-17","article-title":"Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor","volume":"61","author":"Coates","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2025.101477_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105907","article-title":"JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase","volume":"227","author":"Bonneux","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2025.101477_bib59","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1099\/vir.0.053025-0","article-title":"The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid","volume":"94","author":"Bakker","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2025.101477_bib60","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/AAC.00211-07","article-title":"RSV604, a novel inhibitor of respiratory syncytial virus replication","volume":"51","author":"Chapman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2025.101477_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009428","article-title":"EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model","volume":"17","author":"Rhodin","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2025.101477_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45241-y","article-title":"Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor","volume":"15","author":"Sake","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2025.101477_sbref59","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo2236","article-title":"Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase","volume":"8","author":"Sourimant","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.coviro.2025.101477_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00800-24","article-title":"Structural basis of paramyxo- and pneumovirus polymerase inhibition by non-nucleoside small-molecule antivirals","volume":"68","author":"Wolf","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2025.101477_bib65","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.79.20.13105-13115.2005","article-title":"Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase","volume":"79","author":"Liuzzi","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101477_bib66","first-page":"1680","article-title":"Characterization of an orally available respiratory syncytial virus L protein polymerase inhibitor DZ7487","volume":"15","author":"Guo","year":"2023","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.coviro.2025.101477_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008517","article-title":"An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model","volume":"6","author":"Krumm","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2025.101477_bib68","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41564-020-0752-7","article-title":"Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase","volume":"5","author":"Cox","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2025.101477_sbref65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011342","article-title":"4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses","volume":"19","author":"Lieber","year":"2023","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2025.101477_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00420-24","article-title":"4'-Fluorouridine inhibits alphavirus replication and infection in vitro and in vivo","volume":"15","author":"Yin","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2025.101477_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.106046","article-title":"Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4'-fluorouridine","volume":"233","author":"Schrell","year":"2025","journal-title":"Antivir Res"},{"key":"10.1016\/j.coviro.2025.101477_bib72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1515\/mr-2023-0047","article-title":"Organoids as preclinical models of human disease: progress and applications","volume":"4","author":"Chen","year":"2024","journal-title":"Med Rev (2021)"},{"key":"10.1016\/j.coviro.2025.101477_bib73","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2025.101477_bib74","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41564-025-01955-3","article-title":"Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice","volume":"10","author":"Dohrmann","year":"2025","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2025.101477_bib75","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.00333-08","article-title":"CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity","volume":"53","author":"Yamashita","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2025.101477_bib76","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.vaccine.2016.11.054","article-title":"Animal models of respiratory syncytial virus infection","volume":"35","author":"Taylor","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2025.101477_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2025.101477_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3002-3","article-title":"Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study","volume":"18","author":"Chatzis","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.coviro.2025.101477_bib79","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/vaccines12050513","article-title":"Age-stratified seroprevalence of respiratory syncytial virus: analysis using prefusion F and G protein antibodies","volume":"12","author":"Nham","year":"2024","journal-title":"Vaccinnes"},{"key":"10.1016\/j.coviro.2025.101477_bib80","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.virol.2009.03.026","article-title":"The origin and global emergence of adamantane resistant A\/H3N2 influenza viruses","volume":"388","author":"Nelson","year":"2009","journal-title":"Virology"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625725000276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625725000276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:47:28Z","timestamp":1772894848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625725000276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":80,"alternative-id":["S1879625725000276"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2025.101477","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of advanced respiratory syncytial virus antiviral therapeutics 2025","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2025.101477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101477"}}